Arbutus Biopharma Corporation (ABUS) Earnings History
Annual and quarterly earnings data from 1998 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -1236.7% | -1133.0% |
| 2023 | 100.0% | -430.5% | -401.6% |
| 2022 | 100.0% | -167.8% | -178.0% |
| 2021 | 100.0% | -669.1% | -693.9% |
| 2020 | -586.7% | -836.1% | -922.0% |
Download Data
Export ABUS earnings history in CSV or JSON format
Free sign-in required to download data
Arbutus Biopharma Corporation (ABUS) Earnings Overview
As of February 28, 2026, Arbutus Biopharma Corporation (ABUS) reported trailing twelve-month net income of -$42M, reflecting +0.1% year-over-year growth. The company earned $-0.22 per diluted share over the past four quarters, with a net profit margin of -11.3%.
Looking at the long-term picture, ABUS's historical earnings data spans multiple years. The company achieved its highest annual net income of $30M in fiscal 2012.
Arbutus Biopharma Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), ABUS has room to improve margins relative to the peer group. Compare ABUS vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$70M | +4.0% | -$76M | $-0.38 | -1133.0% | -1236.7% |
| 2023 | -$73M | -4.9% | -$78M | $-0.44 | -401.6% | -430.5% |
| 2022 | -$69M | +8.9% | -$65M | $-0.46 | -178.0% | -167.8% |
| 2021 | -$76M | -19.6% | -$74M | $-0.73 | -693.9% | -669.1% |
| 2020 | -$64M | +58.5% | -$58M | $-0.86 | -922.0% | -836.1% |
| 2019 | -$154M | -169.2% | -$144M | $-2.69 | -2557.4% | -2394.0% |
| 2018 | -$57M | +32.3% | -$90M | $-1.03 | -967.8% | -1522.0% |
| 2017 | -$84M | +78.0% | -$111M | $-1.54 | -788.8% | -1036.4% |
| 2016 | -$384M | -528.4% | -$492M | $-7.24 | -25606.7% | -32773.3% |
| 2015 | -$61M | -57.5% | -$102M | $-1.34 | -245.7% | -411.4% |
See ABUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABUS vs AGIO
See how ABUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABUS growing earnings?
ABUS EPS of $-0.22 reflects slowing growth at +0.1%, below the 5-year CAGR of N/A. TTM net income is $-42M. Expansion rate has moderated.
What are ABUS's profit margins?
Arbutus Biopharma Corporation net margin is -11.3%, with operating margin at -12.4%. Below-average margins reflect competitive or cost pressures.
How consistent are ABUS's earnings?
ABUS earnings data spans 1998-2024. The current earnings trend is +0.1% YoY. Historical data enables comparison across business cycles.